---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056901"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:04:01.486252+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atara Q1 net loss narrows to $31.8M; tab-cel BLA on track for Q2 2024 submission

## Summary
- Q1 2024 net loss of $31.8M ($0.23/sh) vs $74.8M ($0.72/sh) in Q1 2023; revenue rose to $27.4M from $1.2M on Pierre Fabre partnership.
- Cash, equivalents, ST investments $46.2M plus AR $35.8M; expects funding into 2027 with potential $80M in tab-cel BLA milestones.
- BLA submission for tab-cel in EBV+ PTLD planned Q2 2024; pivotal data showed 48.8% ORR (p<0.0001); Swissmedic approval received.
- ATA3219 lupus nephritis study to start Q4 2024; initial data H1 2025; new SLE cohort without lymphodepletion also in Q4 2024.
- Full-year 2024 operating expenses expected to decrease ~35% vs 2023; restructuring cut workforce by 25% to 170 employees.

## SEC filing metadata
- accession: 0000950170-24-056901
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017024056901/0000950170-24-056901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017024056901/atra-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056901
- JSON: https://secwatch.observer/filing/0000950170-24-056901.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056901.txt

## Key facts
- Earnings Releases
  Atara Biotherapeutics, Inc. reported financial results for first quarter 2024.
  - Period: first quarter 2024
  - Result: reported results
  source text: Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017024056901/0000950170-24-056901-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.